Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

Bibliography

• Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7(10):3129-40
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Barete S, et al. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 2010;9(2):275-87
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16(19):4853-63
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18(8):2290-300
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
   PubMed Web of Science ®Google Scholar
• Coriat R, Nicco C, Chereau C, et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012;11(10):2284-93
   PubMed Web of Science ®Google Scholar
• Hwang PM, Bunz F, Yu J, et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001;7(10):1111-17
   PubMed Web of Science ®Google Scholar
• Alexandre J, Batteux F, Nicco C, et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 2006;119(1):41-8
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(8):760-7
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552-62
   PubMed Web of Science ®Google Scholar
• Cella D, Escudier B, Rini B, et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013;108(8):1571-8
   PubMed Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14(13):1287-94
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31(30):3791-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(3):286-96
   PubMed Web of Science ®Google Scholar
• Pecuchet N, Lebbe C, Mir O, et al. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer 2012;107(3):455-61
   PubMed Web of Science ®Google Scholar
• Mir O, Boudou-Rouquette P, Larousserie F, et al. Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol 2012;23(3):807-9
   PubMed Web of Science ®Google Scholar
• Hu S, Niu H, Inaba H, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103(11):893-905
   PubMed Web of Science ®Google Scholar
• Kosmider O, Chapuis N, Kaltenbach S, et al. Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis. Clin Lymphoma Myeloma Leuk 2013;13(3):347-50
   PubMed Web of Science ®Google Scholar
• Coriat R, Mir O, Ropert S, et al. A painful cranial bulge. Lancet 2011;377(9779):1777
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121(23):4655-62
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. ASCO Meeting Abstracts 2013;31(18 Suppl):4
   Google Scholar
• Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167(5):643-50
   PubMed Web of Science ®Google Scholar
• Shen CT, Qiu Z, Luo QY. Sorafenib in radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 2014;21(2):253-61
   PubMed Web of Science ®Google Scholar
• Haraldsdottir S, Shah MH. An update on clinical trials of targeted therapies in thyroid cancer. Curr Opin Oncol 2014;26(1):36-44
   PubMed Web of Science ®Google Scholar
• Escudero-Ortiz V, Perez-Ruixo JJ, Valenzuela B. Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. Ther Drug Monit 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009;49(4):1109-14
   PubMed Web of Science ®Google Scholar
• Heinz WJ, Kahle K, Helle-Beyersdorf A, et al. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol 2011;68(1):239-45
   PubMed Web of Science ®Google Scholar
• Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011;412(11-12):1060-7
   PubMed Web of Science ®Google Scholar
• Bobin-Dubigeon C, Heurgue-Berlot A, Bouche O, et al. A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. Ther Drug Monit 2011;33(6):705-10
   PubMed Web of Science ®Google Scholar
• Lankheet NA, Hillebrand MJ, Rosing H, et al. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2013;27(4):466-76
   PubMed Web of Science ®Google Scholar
• Gotze L, Hegele A, Metzelder SK, et al. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 2012;413(1-2):143-9
   PubMed Web of Science ®Google Scholar
• Couchman L, Birch M, Ireland R, et al. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2012;403(6):1685-95
   PubMed Web of Science ®Google Scholar
• Andriamanana I, Gana I, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2013;926:83-91
   PubMed Web of Science ®Google Scholar
• Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011;50(9):551-603
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8(25):2249-53
   PubMed Web of Science ®Google Scholar
• Hornecker M, Blanchet B, Billemont B, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs 2012;30(5):1991-2000
   PubMed Web of Science ®Google Scholar
• Tod M, Mir O, Bancelin N, et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011;28(12):3199-207
   PubMed Web of Science ®Google Scholar
• Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57(5):685-92
   PubMed Web of Science ®Google Scholar
• Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012;18(7):2099-107
   PubMed Web of Science ®Google Scholar
• Lagas JS, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010;9(2):319-26
   PubMed Web of Science ®Google Scholar
• Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15(19):6062-9
   PubMed Web of Science ®Google Scholar
• Hu S, Mathijssen RH, de Bruijn P, et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 2014;110(4):894-8
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Hu S, Roberts JL, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013;19(6):1458-66
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 2012;7(8):e42875
   PubMed Web of Science ®Google Scholar
• Gomo C, Coriat R, Faivre L, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs 2011;29(6):1511-14
   PubMed Web of Science ®Google Scholar
• Noda S, Shioya M, Hira D, et al. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol 2013;72(1):269-72
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27(11):1800-5
   PubMed Web of Science ®Google Scholar
• Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358(1):95-7
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 2012;17(9):1204-12
   PubMed Web of Science ®Google Scholar
• Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 2014;53(2):185-96
   PubMed Web of Science ®Google Scholar
• Durand JP, Blanchet B, Buyse M, et al. Relationship between intestinal function and exposure to sorafenib and sunitinib in cancer patients. Ann Oncol 2012;23(Suppl 9):ix73-ix94
   Google Scholar
• Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008;27(3):328-39
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, De Giorgi U, et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20(5):807-15
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104(2):93-113
   PubMed Web of Science ®Google Scholar
• Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144(7):886-92
   PubMed Web of Science ®Google Scholar
• Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27(23):e59-61
   PubMed Web of Science ®Google Scholar
• Franck N, Barete S, Moguelet P, et al. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. J Clin Oncol 2010;28(31):e640-2
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012;13(10):1020-4
   PubMed Web of Science ®Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15(4):1411-16
   PubMed Web of Science ®Google Scholar
• Henin E, Blanchet B, Boudou-Rouquette P, et al. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). Cancer Chemother Pharmacol 2014;73(2):287-97
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99(1):159-65
   PubMed Web of Science ®Google Scholar
• Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010;21(8):1618-22
   PubMed Web of Science ®Google Scholar
• Coriat R, Mir O, Goldwasser F, et al. Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib? Hepatology 2011;54(5):1890-1; author reply 91
   PubMed Web of Science ®Google Scholar
• Coriat R, Gouya H, Mir O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One 2011;6(2):e16978
   PubMed Web of Science ®Google Scholar
• Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100(20):1454-63
   PubMed Web of Science ®Google Scholar
• Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013;108(2):311-18
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21(8):1594-8
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108(5):1034-41
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012;7(5):e37563
   PubMed Web of Science ®Google Scholar
• Lam MK, Al-Ansari S, van Dam GM, et al. Single-chain VEGF/Cy5.5 targeting vegf receptors to indicate atherosclerotic plaque instability. Mol Imaging Biol 2013;15(3):250-61
   PubMed Web of Science ®Google Scholar
• Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs 2011;29(6):1497-9
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26(32):5204-12
   PubMed Web of Science ®Google Scholar
• Loriot Y, Boudou-Rouquette P, Billemont B, et al. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 2008;19(11):1975
   PubMed Web of Science ®Google Scholar
• Oh D, Park HC, Lim HY, Yoo BC. Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction. Radiat Oncol J 2013;31(3):171-4
   PubMedGoogle Scholar
• Barney BM, Markovic SN, Laack NN, et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 2013;87(1):73-80
   PubMed Web of Science ®Google Scholar
• Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014;89(1):179-96
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011;68(5):1111-18
   PubMed Web of Science ®Google Scholar
• Mazard T, Causse A, Simony J, et al. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Mol Cancer Ther 2013;12(10):2121-34
   PubMed Web of Science ®Google Scholar
• Samalin E, Bouche O, Thezenas S, et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer 2014;110(5):1148-54
   PubMed Web of Science ®Google Scholar
• Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43(1):55-63
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14(12):1233-42
   PubMed Web of Science ®Google Scholar
• Arrondeau J, Mir O, Boudou-Rouquette P, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2012;30(5):2046-9
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Carton E, Mir O, et al. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. Invest New Drugs 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mir O, Blanchet B, Goldwasser F. Drug-induced effects on erlotinib metabolism. N Engl J Med 2011;365(4):379-80
   PubMed Web of Science ®Google Scholar
• Hescot S, Vignaux O, Goldwasser F. Pancreatic atrophy – a new late toxic effect of sorafenib. N Engl J Med 2013;369(15):1475-6
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Boudou-Rouquette P, et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012;23(1):280-1
   PubMed Web of Science ®Google Scholar
• Coriat R, Ropert S, Mir O, et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011;29(5):1090-3
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Gregory T, et al. Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents. Invest New Drugs 2011;29(4):716-18
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010;28(6):1054-60
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol 2010;249(2):132-9
   PubMed Web of Science ®Google Scholar
• Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012;30(32):4017-25
   PubMed Web of Science ®Google Scholar